ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by ...
ORION CORPORATION PRESS RELEASE 23 APRIL 2026 at 09.00 EEST Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in ...
Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...
Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial. For patients with malignant pleural mesothelioma — which makes up about 90 ...
Prasad Adusumilli and colleagues have shown that CAR T cells that start to lose power can be revived by immunotherapy drugs given several weeks later. Mesothelioma is a rare cancer that affects the ...
VT3989, a transcriptional enhanced associate domain autopalmitoylation inhibitor, targets the Hippo pathway in mesothelioma treatment. The FDA's fast track designation aims to expedite VT3989's ...
Mesothelioma, a type of lung cancer highly associated with asbestos exposure, has a five-year survival rate of only 10%. Following the CheckMate 743 trial, the dual immune checkpoint inhibitor (ICI) ...
Mesothelioma.us, a free online resource that features comprehensive resources for people who have been diagnosed with mesothelioma, has just unveiled three new tips ...
Over the past 15 or 20 years, a rare form of cancer known as mesothelioma has become increasingly common – affecting as many as 3,000 Americans each year. Additionally, roughly 2,500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results